Rinolan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rinolan

Property Description
Active ingredient Loratadine
Form Tablet, syrup, oral solution
Pharmacological class Second-generation H₁-receptor antagonist
Common use Symptomatic relief of allergic conditions
Origin Synthetic compound (tricyclic piperidine derivative)

What Type of Medicine is Rinolan and What is its Composition?

Rinolan is a single-ingredient, synthetic medication containing the active compound, Loratadine, and is classified as a second-generation antihistamine. It is administered via the oral route in formats such as the tablet, syrup, and oral solution dosage forms. The specific product is often available as an Over-the-Counter (OTC) medicine in various markets.

The active ingredient, Loratadine, is recognized globally for its role in healthcare and is included on lists of essential medicines. Loratadine is chemically defined as a tricyclic piperidine derivative, ensuring consistency and predictability in its action.


How Does the Antihistamine Class Define Rinolan’s Purpose?

Rinolan is a selective peripheral H₁ blocker, functioning as an anti-allergic agent whose primary purpose is to provide foundational histamine antagonism. This classification distinguishes it from older agents because it is engineered to have minimal ability to cross the blood-brain barrier. This targeted action contributes to its designation as a non-sedating and long-acting medication, clinically recognized for its sustained effect.

Its defined function offers relief for common scenarios, such as mitigating the discomfort associated with seasonal allergies. Loratadine preferentially targets and blocks peripheral H₁ histamine receptors. This mechanism means the medicine helps to reduce discomfort by preventing the chemical trigger of allergies from fully initiating an immune response, providing reliable, sustained symptomatic relief of allergy and H₁-histamine receptor-mediated reactions in both adults and pediatric patients.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. NIH Monograph

What side effects are possible with Rinolan?

Possible side effects and safety information

Regulatory documents organize the safety profile of Rinolan (loratadine) by classifying reported adverse reactions based on their frequency and the system-organ class (SOC) affected. The most frequently reported effects from clinical trials are grouped into the Common category.


Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (affecting up to 1 in 10 people in clinical studies) typically include headache, somnolence (drowsiness), increased appetite, and insomnia. For children aged 6 to 12 years, the common reactions reported are headache, nervousness, and fatigue. The safety profile also formally lists reactions reported during post-marketing surveillance, which are generally classified as Very Rare (may affect up to 1 in 10,000 people).

Very Rare reactions involve several SOC groups, including Nervous System Disorders (e.g., dizziness, convulsion) and Cardiac Disorders (e.g., tachycardia, palpitation). Reactions affecting the Hepatobiliary Disorders class, described as abnormal hepatic function, are also listed as Very Rare.


Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources, though rare, include severe hypersensitivity reactions such as anaphylaxis and angioedema, as well as convulsion and abnormal hepatic function. The medicine is contraindicated in patients with a known hypersensitivity to loratadine or any excipients.

Specific Population-Specific Considerations are noted in official labeling. Caution is required when administering the medicine to patients with severe hepatic impairment, as drug elimination may be altered. Furthermore, the risk of somnolence is formally documented as dose-related, being observed more frequently at doses higher than recommended. The compound is also known to be excreted in breast milk.

Overdose and Emergency Response

The official regulatory guidance for Rinolan (Loratadine) overdose focuses on specific clinical manifestations and the immediate, mandated emergency response required.

Documented Overdose Presentations

Documented presentations of overdose include the central nervous system sign of somnolence (drowsiness), the cardiovascular sign of tachycardia (fast heart rate), and the symptom of headache. Over-ingestion is also formally associated with an increased occurrence of anticholinergic symptoms. Severe outcomes reported in regulatory documents include rare but serious neurological events such as convulsions.


Emergency Action and Supportive Management

Official guidance strictly mandates that individuals get medical help or contact a Poison Control Center right away in all cases of suspected overdose. Management requires the prompt institution of general symptomatic and supportive measures. Treatment procedures described in official texts include the possible use of activated charcoal and the consideration of gastric lavage to reduce absorption. Following initial emergency intervention, medical monitoring of the patient is to be continued.


Specific Overdose Considerations

In the pediatric population, specific concerns are documented following syrup overdose, including the occurrence of extrapyramidal signs and palpitations. When gastric lavage is considered for children, normal saline solution is specified as the preferred solution. There is no specific antidote listed in the official prescribing information for Loratadine overdose, and the drug is officially documented not to be removed by haemodialysis.

Therapeutic Uses of Rinolan

What Rinolan Treats: Main Uses and Benefits

Rinolan is commonly used to help with symptomatic relief for conditions related to inflammatory or irritative states, primarily associated with allergies. It is applied across domains where additional symptomatic support is needed to manage a combination of distressing symptoms. This class of medicine is generally considered relevant for managing acute and chronic allergic manifestations.


Symptom Relief and Supportive Domains

Rinolan is commonly used across conditions presenting with acute episodes of allergic rhinitis, which may be seasonal or perennial, and for managing hives (urticaria). This may include helping with symptoms such as frequent sneezing, runny nose, nasal itching, and skin redness and itching. It may assist with symptom clusters that create noticeable interference with daily stability. Symptomatic relief may contribute to helping patients cope more steadily when symptoms intensify.

Rinolan supports the patient during difficult episodes by easing distress. This may assist with maintaining functional stability and contribute to improved comfort across different patient groups.


Quick Fact: Relief for Itching Rinolan is relevant for easing symptoms that interfere with daily comfort, particularly those related to persistent skin itching and allergic manifestations.

Regulatory References

  1. NIH MedlinePlus overview on allergy medications

Eligibility and Restrictions for Use

Who Can and Cannot Use Rinolan?

The official eligibility profile for Rinolan (Loratadine) is governed by specific rules regarding age, physiological state, and pre-existing conditions as documented in regulatory labels.

Eligibility Category Status (As Stated in Labeling)
Populations for whom use is allowed Adults, adolescents, and children 2 years of age and older are eligible for use [Source: FDA, NHS].
Populations for whom use is contraindicated Patients with a known hypersensitivity to Loratadine, its metabolite, or any formulation excipients [Source: EMA/SmPC].
Age-related eligibility rules Safety and effectiveness for use in children younger than 2 years have not been established [Source: FDA, EMA/SmPC].
Condition-specific eligibility rules Use is restricted in patients with severe hepatic (liver) impairment and severe renal (kidney) impairment due to reduced clearance [Source: EMA/SmPC, NIH].
Pregnancy and lactation eligibility Use is generally not recommended during pregnancy and is contraindicated in breastfeeding women due to excretion into breast milk [Source: EMA/SmPC].

These official regulatory statements define the final boundaries for who may use the medicine. Hypersensitivity and use during lactation are formally defined exclusions, while patients with severe organ impairment are restricted populations for whom use is conditional.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details official information regarding Rinolan (Loratadine) interactions with other medicinal products and diagnostic procedures, as documented in authoritative regulatory sources.

Potential Drug-Drug Interactions (DDIs)

Loratadine undergoes extensive metabolism, primarily through certain liver enzymes. Concomitant use with medicinal products that inhibit these enzymes—such as those that are strong inhibitors of CYP3A4 or CYP2D6—may result in increased plasma concentrations of Loratadine.

Specific examples of medicines that have been reported in controlled trials to increase Loratadine plasma concentrations include the antibiotic Erythromycin, the antifungal agent Ketoconazole, and the histamine-2 antagonist Cimetidine. While increased concentrations were observed, these were reported in trials without clinically significant changes, including those related to heart function.

Patients with pre-existing conditions that affect Loratadine's clearance, such as severe hepatic impairment, may require careful assessment of potential drug interactions.

Interactions with Diagnostic Tests

Use of Loratadine interferes with the results of certain diagnostic procedures. It is officially required to discontinue use of Loratadine for approximately 48 hours prior to scheduling or performing any skin prick or intradermal sensitivity testing. This temporary cessation ensures the validity and accuracy of the diagnostic test results, as the antihistamine activity of the medicine can otherwise suppress the expected response.

Mechanism of Action

Rinolan exerts its effect by acting as a selective antagonist of peripheral mathbfH1 histamine receptors, thereby modulating pathways dependent on Histamine H1 receptor activation. The mechanism is confined to the biological processes initiated by Histamine, leading to changes in H1-mediated physiological function.


Peripheral Receptor Blockade and System Modulation

The primary molecular interaction involves the binding of the active drug, Descarboethoxyloratadine, to H1 receptors outside the central nervous system. This competitive blockade directly suppresses the Histamine signal, modifying the early molecular steps that would otherwise trigger vascular leakage and sensory nerve activation. The resulting physiological effect is the inhibition of H1-mediated changes in vascular permeability and the inhibition of H1-mediated nerve signals.


Low CNS Penetration and Sustained Mechanism

This domain addresses the structural constraint of low Blood-Brain Barrier (BBB) penetration, which limits the drug's activity to the periphery. The mechanism engages biological systems by ensuring the drug does not significantly interfere with central H1 receptor function, resulting in a low potential for central H1 receptor binding. The effect is further sustained by the prolonged half-life of the active metabolite, contributing to sustained receptor blockade within targeted peripheral pathways.

Dosage and Administration Information

How Rinolan (Loratadine) is Used in Clinical Practice

Rinolan, which contains the active ingredient Loratadine, is administered via the oral route as a once-daily, standardized regimen. The product is available in several dosage forms, including the tablet, oral solution (syrup), and orally disintegrating tablet (ODT). Use of Rinolan is not dependent on mealtimes and can be taken with or without food.


Standard Dosing Regimens

The standard dose is based primarily on the patient's age. The usual recommended dose for adults and adolescents 12 years of age is 10 mg once daily. Children aged 6 to 11 years are also typically administered 10 mg once daily. For younger children aged 2 to 5 years, the dose is typically 5 mg once daily (or 5 mL of oral solution).


Population Adjustments and Procedural Conditions

Dose adjustments are applied for certain patient populations. For adults and children 6 years and older with severe hepatic impairment or severe renal impairment (creatinine clearance < 30 mL/min), the administration frequency is generally reduced to 10 mg every other day. When using the liquid or syrup form, a calibrated measuring device must be used for accurate dosing. Furthermore, to prevent interference with test results, administration of Rinolan must be discontinued for at least 48 hours before any planned cutaneous (skin) allergy tests.

Recent Clinical Evidence

Clinical Research Evidence / Overview of Studies

This section outlines the key findings from clinical research and literature reviews concerning the co-administration of Drug X and Drug Y for Osteoarthritis (OA).


Research on Co-administration for Osteoarthritis

Research has investigated whether the co-administration of Drug X and Drug Y was associated with specific outcomes compared to other strategies, including monotherapy with either compound. Studies evaluated whether the combination was associated with a reduction in both pain and inflammation. Researchers also examined the time course of observed changes in pain measures over the initial period of study.

  • Comparative Analysis: Comparative studies were conducted to evaluate whether the combination was associated with different outcomes when compared to other single-agent therapies.
  • Target Population: Research has primarily focused on adults diagnosed with mild to moderate OA, mainly involving the knee joint.

Drug X Monotherapy: Findings on Joint Function

Studies investigated whether the administration of Drug X was associated with changes in measures of long-term joint function. The measurement of pain reduction was typically assessed using validated patient-reported outcome scales.

  • Safety Profile: The safety profile was evaluated primarily in participants under the age of 65. Research has explored the administration of Drug X in populations with liver impairment, and findings were noted by study researchers.

Drug Y Monotherapy: Anti-Inflammatory Studies

Drug Y is a non-steroidal anti-inflammatory compound. Studies have investigated whether its administration was associated with measures of reduced inflammation or tissue changes.

  • Observed Events: The most frequently reported adverse events in the studies were consistent with common gastrointestinal symptoms. Regulatory bodies evaluated the findings from Phase III trials regarding the potential clinical use of the combination.

Key Studies & References Recent advances in the management of knee osteoarthritis: a narrative review

Frequently Asked Questions (FAQ)

Common questions about Rinolan (FAQ)


Q: Can Rinolan be taken with other cold and flu medicines?

Official product information notes that using Rinolan alongside medicines known to inhibit certain liver enzymes may increase the concentration of Rinolan in the body. Regulatory warnings mention the need for awareness regarding the potential additive effects of other medicines that may cause drowsiness, dry mouth, or difficulty urinating.


Q: Are there any food or drinks I need to avoid while using Rinolan?

The active ingredient in Rinolan can be administered with or without food. However, information regarding the presence of phenylalanine is noted in regulatory documents for specific dosage forms, such as chewable tablets, for patients with phenylketonuria (PKU).


Q: Does Rinolan interact with alcohol?

Official studies have been conducted to investigate the co-administration of Rinolan with alcohol. These studies indicate that the active ingredient, when used with alcohol, does not have potentiating effects as measured by tests of psychomotor performance.


Q: Can Rinolan affect my ability to drive?

While Rinolan is classified as a non-sedating antihistamine, somnolence (drowsiness) is formally listed as a common side effect in regulatory documents. Regulatory documents include warnings that potential users should consider the risk of impairment, such as drowsiness, before driving or operating machinery.


Q: Can Rinolan affect my mood or cause anxiety?

Regulatory documents list certain adverse events that relate to the nervous system. Among these are insomnia (difficulty sleeping) and nervousness.


Q: What happens if I miss a dose of Rinolan?

Regulatory guidance includes information describing the established procedure for addressing a missed dose. The established procedure for a missed dose is to administer it at the time it is remembered, unless this time is close to the next scheduled administration. Guidance states that two doses should not be administered at one time.


Q: Is the research evidence for Rinolan well-established?

The active ingredient is recognized globally for its role in healthcare. Its inclusion on the World Health Organization (WHO) Model List of Essential Medicines indicates its established position and acceptance in clinical use.


Q: Can Rinolan be crushed or split if it's a tablet?

The acceptability of altering the drug depends on the specific formulation. For example, some chewable tablets are officially instructed to be chewed or crushed completely before being swallowed. It should be noted that standard tablet forms may not carry this same instruction.


Q: Is Rinolan available over the counter, or do I need a prescription?

In many markets, this medicine is approved and available as an Over-the-Counter (OTC) drug. However, certain strengths or specific dosage forms may still be available through a prescription.


Q: How quickly should I expect Rinolan to start working?

Clinical research has examined the time of onset of action for symptom relief. Findings indicate that observed relief can occur within 1 to 3 hours after administration.


Q: Is Rinolan safe for use during pregnancy?

Official labeling generally states that use during pregnancy is not recommended due to the lack of sufficient data from human studies. Official labeling states that regulatory bodies continuously evaluate the safety and risk profile for all populations.


Q: Can Rinolan be used by older adults (seniors)?

Use is generally allowed for older adults. Regulatory documents note specific considerations for patients with pre-existing severe hepatic (liver) or renal (kidney) impairment, where drug clearance may be reduced.


Q: Why are people talking about Rinolan and sleep issues?

While the drug is classified as a non-sedating antihistamine, the regulatory documents formally list side effects that relate to sleep. These include both somnolence (drowsiness) and insomnia (difficulty sleeping) among the reported adverse reactions.


Q: Is there a link between Rinolan and weight changes?

Regulatory documents list increased appetite as a common adverse reaction in certain age groups.


Q: Does Rinolan contain lactose or gluten?

The inclusion of inactive ingredients depends on the specific formulation. Certain tablet forms are documented to contain lactose monohydrate. Some official product labeling also states that the formulation is gluten free.


Q: Are there different strengths of Rinolan available?

Official regulatory documents and guidance indicate that the product is commonly available in strengths of 5 mg and 10 mg in various dosage forms.


Q: Can Rinolan cause strange dreams or nightmares?

Adverse event reports, though generally rare, have included descriptions of paroniria (abnormal dreams) among the psychiatric disorders listed in official sources.


Q: Can Rinolan cause stomach upset or nausea?

Gastrointestinal disorders are included in the documented side effect profile. Regulatory documents formally list nausea and gastritis among the very rare adverse reactions reported.


Q: What is the half-life of Rinolan?

Pharmacokinetic studies provide factual data on how the body processes the drug. The half-life of the parent drug (Loratadine) is approximately 8 to 10 hours, and the half-life of its primary active metabolite is approximately 20 hours.


Q: Is Rinolan a newer or older medication?

The active ingredient is formally classified as a second-generation H₁-receptor antagonist. This classification distinguishes it from older, first-generation antihistamines based on its structural properties.


Q: What is the difference between Rinolan and a generic version of the drug?

Regulatory standards require that generic versions must contain the identical active ingredient, be the same strength and dosage form, and be demonstrated as bioequivalent to the brand-name product.


Q: Is it normal to feel thirsty after taking Rinolan?

Reported adverse events, though generally rare, have included the side effect of thirst among the descriptions of autonomic nervous system effects listed in official sources.


Q: How is the active ingredient in Rinolan metabolized by the body?

The active ingredient is extensively metabolized in the liver by certain cytochrome P450 enzymes to produce its main active metabolite, Descarboethoxyloratadine.


Q: Do children need a special formulation of Rinolan?

The product is manufactured and available in multiple dosage forms, including a tablet, oral solution (syrup), and orally disintegrating tablet (ODT). This variety allows for appropriate administration across the eligible pediatric age groups.

How should Rinolan be stored and disposed of?

How to Store and Dispose of Rinolan?

Storage of Rinolan (loratadine) must strictly follow official regulatory requirements to maintain product stability and safety.

Storage Conditions

Rinolan must be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medicine requires protection from excessive moisture and, for some forms, light. Liquid preparations must not be frozen.

All dosage forms must be stored in their original container, which should be kept tightly closed. Do not use the medicine if the packaging seal or blister unit appears broken or compromised.

Disposal and Child Safety

Rinolan must be kept out of the sight and reach of children.

Unused or expired product should not be disposed of in household wastewater or trash. You must consult local regulations or a pharmacist for guidance on proper disposal of medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rinolan found in:

A-Z Index: